STAAR Surgical Company
26.59-0.57 (-2.1%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · STAA · USD
Key Stats
Market Cap
1.31BP/E (TTM)
-Basic EPS (TTM)
-1.93Dividend Yield
0%Recent Filings
8-K
Q3 sales up 6.9% on China payment
STAAR Surgical reported preliminary Q3 2025 net sales of $94.7 million, up 6.9% from $88.6 million last year, boosted by $25.9 million from a deferred December 2024 China shipment paid in full this quarter. Growth outside China rose 7.7%, but new orders there dipped due to distributor inventory cuts. This timing quirk lifted results ahead of the October 23 stockholder vote on the Alcon merger. China inventory now aligns at six months.
10-Q
Q2 FY2025 results
STAAR Surgical's Q2 FY2025 net sales fell 55% y/y to $44.3M, driven by a sharp drop in China from distributor inventory drawdowns, though Americas and EMEA grew 10% and 11% respectively; gross margin slipped to 74.0% from 79.2% on lower volumes. Restructuring charges of $27.9M YTD fueled an operating loss of $87.4M and net loss of $71.0M, or $(1.44) diluted EPS on 49.4M shares—anti-dilutive due to the loss. Cash climbed to $167.1M with $22.8M from investing, while free cash flow stood negative at $(36.2M) (derived). Post-quarter, Alcon announced a $28/share merger, pending approvals. Uncertainty lingers over China tariffs.
8-K
Q2 sales plunge on China inventory
STAAR Surgical reported Q2 2025 net sales of $44.3 million, down 55% year-over-year from $99.0 million, hammered by a planned inventory drawdown in China that slashed regional revenue to $5.3 million. Yet excluding China, sales climbed 10% to $39.0 million, fueled by gains in other markets, while gross margin held at 74.0% amid volume dips but cost controls. Restructuring charges of $5.2 million contributed to a $16.8 million net loss. Pending Alcon acquisition disrupts operations. Cash stands at $189.9 million.
8-K
Alcon acquires STAAR for $1.5B
STAAR Surgical agreed to merge with Alcon on August 4, 2025, for $28 per share in cash, valuing the company at $1.5 billion—a 51% premium to its prior close. This bolsters Alcon's refractive surgery portfolio amid rising global myopia, yet STAAR faces headwinds from fluctuating China demand. Deal closes in 6-12 months, pending shareholder and regulatory nods. Termination fees loom if it unravels.
8-K
STAAR appoints CFO, forms committee
STAAR Surgical appointed Deborah Andrews as permanent Chief Financial Officer on June 25, 2025, after her interim role since March, leveraging her two-decade tenure at the company. The board also formed a Capital Stewardship Committee, chaired by Lilian Y. Zhou, to oversee capital allocation amid growth prospects and strong cash flows. This bolsters financial rigor, accelerating the targeted $225 million annual SG&A run rate. Yet restructuring claims VP Brian Moore, departing June 27.
IPO
Website
Employees
Sector
Industry
ALC
Alcon Inc.
73.60-1.22
BLCO
Bausch + Lomb Corporation
15.47+0.27
COO
The Cooper Companies, Inc.
69.58-2.17
ISRG
Intuitive Surgical, Inc.
537.59-7.80
LNSR
LENSAR, Inc.
11.90+0.03
POCI
Precision Optics Corporation, I
4.26-0.01
RXST
RxSight, Inc.
8.43-0.38
SGHT
Sight Sciences, Inc.
5.04-0.13
SSII
SS Innovations International In
8.65+0.13
STSS
Sharps Technology Inc.
4.96-0.19